Upadacitinib
Cat. No.：YN340219
CAS No. ：1310726-60-3
| 产品名称: | Upadacitinib |
| CAS No.: | 1310726-60-3 |
| Chemical Name: | (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-1-pyrrolidinecarboxamide |
| Synonyms: | 乌帕替尼; ABT-494 |
| 分子量: | 380.37 |
| 分子式: | C₁₇H₁₉F₃N₆O |
| SMILES: | O=C(N1C[C@@H](CC)[C@@H](C2=CN=C3C=NC(NC=C4)=C4N32)C1)NCC(F)(F)F |
| 存储: | Please store the product under the recommended conditions in theCertificate of Analysis. |
| 运输: | Room temperature in continental US; may vary elsewhere. |
| 产品描述: | Upadacitinib (ABT-494) 是一种高效的、具有口服活性的、选择性 Janus 激酶 1 (JAK1) 抑制剂 (IC50=43 nM)。Upadacitinib 对 JAK1 的选择性约为 JAK2 (200 nM）的 74 倍。Upadacitinib 可用于多种自身免疫性疾病的研究。 |
| IC50和靶点: | [{name:"JAK1:0.043 μM (IC50)"},{name: "JAK2:0.2 μM (IC50)"},{name: "JAK3:2.3 μM (IC50)"},{name: "Tyk2:4.7 μM (IC50)"}] |
| In Vitro: | |
| In Vivo: | |
| Clinical Trial: | |
| Solvent & Solubility: |
Parmentier, J.M., Voss, J., Graff, C., et al.In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)BMC Rheumatol.2,23(2018)
